• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 3, 2017

View Archived Issues

In the clinic

AIT Therapeutics Inc., of New York, said investigators at the National Heart, Lung and Blood Institute completed treatment of a patient with treatment-refractory Mycobacterium abscessus lung disease with the AIT Nitric Oxide generator system under the FDA compassionate use program. Read More

Other news to note

Mallinckrodt plc, of Staines-upon-Thames, U.K., said it is acquiring Ocera Therapeutics Inc., of Redwood City, Calif., a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for orphan and liver diseases. Read More

Earnings

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported U.S. net sales of constipation drug Linzess (linaclotide), as reported by partner Allergan plc, of Dublin, totaling $190.9 million for the third quarter, up 16 percent over the third quarter in 2016. Read More

Financings

Spero Therapeutics Inc., of Cambridge, Mass., priced its IPO of 5.5 million shares at $14 per share, the low end of its previously proposed range, for gross proceeds of $77 million. The company granted underwriters a 30-day option to purchase up to 825,000 additional common shares, which could add up to $11.6 million to the proceeds. Read More

Medicare's 340B cuts pit biopharma against hospital industry

If it stands up against promised challenges, a new payment rule that would let the Centers for Medicare & Medicaid Services (CMS) cash in on some of the outpatient drug savings U.S. hospitals get through the 340B discount program could deepen the pricing rift between hospital groups and the biopharma industry. Read More

Microbiome's influence on checkpoint blockade is confirmed in clinic

A lot of effort has been expended on understanding what determines the efficacy of checkpoint blockade. Much of that effort has been focused on the tumor and the immune system – reasonably enough, since those are the direct combatants in the tumor-immune face-off. Read More

U.K. aims to align with updated EU clinical trial regulations despite Brexit

LONDON – Further uncertainty has been added to the stew of Brexit imponderables after the British government confirmed that the long-awaited Clinical Trials Regulation will not be transposed into U.K. law when the country leaves the EU in March 2019. Read More

Advicenne seeking $41M in Euronext IPO for EU filing, U.S. pivotal trial

DUBLIN – Advicenne SA set out its stall this week with plans to raise up to €35 million (US$41 million) in an IPO on the Euronext in Paris, in order to continue clinical development of its lead therapy, ADV-7103, and to initiate the commercial rollout of the product in Europe. Read More

Boehringer seals $201M Dicerna deal targeting NASH and other liver diseases

Boehringer Ingelheim GmbH is enlisting early stage RNAi specialist Dicerna Pharmaceuticals Inc. to discover and develop new therapies for chronic liver diseases, starting with nonalcoholic steatohepatitis (NASH). Read More

Regulatory front

The FDA released a draft guidance on controlled correspondence regarding generic drug development. A revision of a draft guidance issued in 2015, the new draft discusses how sponsors can submit controlled correspondence requesting information related to generic drug development and how the agency responds to such requests. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe